Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a signific...
Velasco, R., Bruna, J., Briani, C., Argyriou, A., Cavaletti, G., Alberti, P., et al. (2014). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, 85(4), 392-398 [10.1136/jnnp-2013-305334].
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
CAVALETTI, GUIDO ANGELO;ALBERTI, PAOLA;FRIGENI, BARBARA;Cortinovis, D;Cazzaniga, M;
2014
Abstract
Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a signific...
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
